INCY - Incyte a new hold at Deutsche Bank as key drugs approach patent cliffs
2024-05-23 12:43:05 ET
More on Incyte
- Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
- Incyte jumps 6%, intends to buy back $2B stock
- Incyte Non-GAAP EPS of $0.64 misses by $0.19, revenue of $880.89M misses by $43.75M
- Incyte Corporation (INCY) Q1 2024 Earnings Call Transcript
- Incyte Corporation 2024 Q1 - Results - Earnings Call Presentation